Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

9/18/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Migpriv

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Acetylsalicylsyra Testmiljö

Acetylsalicylsyra

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Briggs G, Freeman RK. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 10th ed; 2015.

  2. Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology 2006;17:435-9.

  3. Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005;192:922-3.

  4. Abe K, Honein MA, Moore CA. Maternal febrile illness, medication use, and the risk of congenital renal anomalies. Birth Defets Research Part A 2003;67:911-8.

  5. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003;68:70-84.

  6. Kozer E, Nikfar S, Costei A et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-30.

  7. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31.

  8. Torfs CP, Katz EA, Bateson TF et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.

  9. Di Sessa TG, Moretti ML, Khoury A et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892-900.

  10. Uzan S, Beaufils M, Breart G et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991;337:1427-31.

  11. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  12. Richards ID. A retrospective enquiry into possible teratogenic effects of drugs in pregnancy. Adv Exp Med Biol 1972;27:441-55.

  1. Briggs G, Freeman RK. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 10th ed; 2015.
  2. Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology 2006;17:435-9.
  3. Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005;192:922-3.
  4. Abe K, Honein MA, Moore CA. Maternal febrile illness, medication use, and the risk of congenital renal anomalies. Birth Defets Research Part A 2003;67:911-8.
  5. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003;68:70-84.
  6. Kozer E, Nikfar S, Costei A et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-30.
  7. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31.
  8. Torfs CP, Katz EA, Bateson TF et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.
  9. Di Sessa TG, Moretti ML, Khoury A et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892-900.
  10. Uzan S, Beaufils M, Breart G et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991;337:1427-31.
  11. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  12. Richards ID. A retrospective enquiry into possible teratogenic effects of drugs in pregnancy. Adv Exp Med Biol 1972;27:441-55.
2 2
2 2

Metoklopramid Testmiljö

Metoklopramid

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.

  2. Berkovitch M, Mazzota P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol. 2002;19:311-6.

  3. Sun L, Xi Y, Wen X, Zou W. Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. PLoS One. 2021;16(9):e0257584.

  4. Ishikawa T, Obara T, Akazawa M, Noda A, Oyanagi G, Morishita K et al. Risk of major congenital malformations associated with first-trimester exposure to propulsives: A health administrative database study in Japan. Pharmacoepidemiol Drug Saf. 2021;0(0):0.

  5. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. FDA Safety Communication 2011-02-22. goo.gl/ZUzLmH [cited 2014-04-25].

  6. Pharmacovigilance Working Party (PhVWP). Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy. European Medicines Agency. http://goo.gl/rhEKu [cited 2014-04-25].

  1. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.
  2. Berkovitch M, Mazzota P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol. 2002;19:311-6.
  3. Sun L, Xi Y, Wen X, Zou W. Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. PLoS One. 2021;16(9):e0257584.
  4. Ishikawa T, Obara T, Akazawa M, Noda A, Oyanagi G, Morishita K et al. Risk of major congenital malformations associated with first-trimester exposure to propulsives: A health administrative database study in Japan. Pharmacoepidemiol Drug Saf. 2021;0(0):0.
  5. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. FDA Safety Communication 2011-02-22. goo.gl/ZUzLmH [cited 2014-04-25].
  6. Pharmacovigilance Working Party (PhVWP). Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy. European Medicines Agency. http://goo.gl/rhEKu [cited 2014-04-25].